Description

Insulin Aspart CAS NO 116094-23-6 is a rapid-acting insulin analog engineered for superior pharmacokinetic control. This recombinant human insulin derivative is critical for managing postprandial glucose levels in diabetic therapy. It is primarily required by pharmaceutical manufacturers for the formulation of advanced insulin injection products and by research institutions for metabolic studies.

Application

• Primary active pharmaceutical ingredient (API) in rapid-acting insulin injection formulations.
• Used in the development and manufacturing of combination insulin therapies (e.g., biphasic insulin aspart).
• Critical reagent in biochemical and pharmacological research on diabetes and insulin signaling pathways.
• Reference standard for quality control and analytical method development in pharmaceutical laboratories.
• Used in clinical trials for evaluating new diabetes treatment modalities and delivery systems.

Basic Information

Product Name	Insulin Aspart
CAS No.	116094-23-6
Molecular Formula	C256H381N65O79S6
Molecular Weight	5825.8 g/mol
Synonyms	Insulin Aspart; B28-Asp-Insulin; Insulin (Human) B28-Asp; Aspart Insulin; NovoRapid (API); NovoLog (API); Insulin X14; B28-aspartic acid-human insulin; IAsp
EINECS	Contact for details

Quality Control

Our Insulin Aspart is manufactured under strict quality systems. It is produced to meet the exacting standards required for pharmaceutical active ingredients, with testing aligned to pharmacopeial monographs (e.g., USP, EP). Our products undergo rigorous quality testing to ensure compliance with industry standards. Certificates of Analysis (COA) are available upon request.

Storage

Preserve in a tightly closed container, protected from light. For long-term stability, store at -20°C or below. Under these conditions, the product is typically stable for several years. For short-term use, store at 2-8°C. The product is hygroscopic (moisture-sensitive).

Specification

Item	Specification
Appearance	White or almost white powder
Identification (HPLC)	Conforms to reference standard
Identification (IR)	Conforms to structure
Assay (HPLC)	≥ 95.0% (on anhydrous basis)
Related Proteins (HPLC)	Meets pharmacopeial requirements
High Molecular Weight Proteins (SEC-HPLC)	≤ 1.0%
Water Content (KF)	≤ 10.0%
Bacterial Endotoxins	< 10 IU/mg
Microbial Enumeration	Meets Ph. Eur. 2.6.12 / USP <61>

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.